Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 8Thoracic 1Plasma cell 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 387Skin Neoplasms 91Carcinoma, Non-Small-Cell Lung 78Breast Neoplasms 56Neoplasms 55Colorectal Neoplasms 52Lung Neoplasms 51Neoplasm Metastasis 46Ovarian Neoplasms 44Lymphoma, T-Cell, Cutaneous 44Carcinoma, Renal Cell 43Squamous Cell Carcinoma of Head and Neck 42Uveal Melanoma 39Pancreatic Neoplasms 37Sarcoma 36Carcinoma, Basal Cell 36Head and Neck Neoplasms 33Uterine Cervical Neoplasms 32Prostatic Neoplasms 32Stomach Neoplasms 30Carcinoma, Hepatocellular 30Endometrial Neoplasms 29Carcinoma, Merkel Cell 29Urinary Bladder Neoplasms 28Kidney Neoplasms 26Triple Negative Breast Neoplasms 24Carcinoma, Squamous Cell 23Esophageal Neoplasms 22Lymphoma 21Mycosis Fungoides 19

Interventions

pembrolizumab 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Liposarcoma, Myxoid × Dermatologic × Clear all
NCT05492682 2026-05-12

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Valo Therapeutics Oy

Phase 1 Recruiting
15 enrolled
BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡